A Double-Blind, Randomized Clinical Trial to Assess the Augmentation with Nimodipine of Antidepressant Therapy in the Treatment of “Vascular Depression”

TARAGANO FE, BAGNATI PM, ALLEGRI RF.

Progress in Neurotherapeutics and Neuropsychopharmacology 2007.

Cambridge University Press

Lugar: Cambridge, UK; Año: 2007; p. 137 - 154

Cerebrovascular disease may cause "vascular depression" (VaD) . Calcium channetblockers are presumed treatments for cerebrovascular disease and might be expected to improve depression and prevent recurrence. We examine the efficacy and tolerability of the use of nimodipine as an augmentation of fluoxetine in the treatment of VaD. In treating VaD, augmentation of fluoxetine with nimodipine led to better treatment results and lower rates of recurrence. These findings support the argumento f antidepressant therapy might be helpful in the treatment of cerebrovascular disease, which is envolved in the patogénesis of this type of depresión.